Literature DB >> 31982921

Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation.

Carolina Pinto Vieira1, Daniel Valente Neves1, Glauco Henrique Balthazar Nardotto1, Evandro José Cesarino1, Adriana Rocha1, Ailton Marcelo Castilho Teno Zanardi2, Vera Lucia Lanchote3.   

Abstract

Entities:  

Keywords:  Chagas disease; Elderly patients; Metabolism; Nebivolol; Pharmacokinetics

Year:  2020        PMID： 31982921     DOI： 10.1007/s00228-020-02837-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  12 in total

1.  Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease.

Authors:  S M Keating; X Deng; F Fernandes; E Cunha-Neto; A L Ribeiro; B Adesina; A I Beyer; P Contestable; B Custer; M P Busch; E C Sabino
Journal:  Int J Cardiol       Date:  2015-07-12       Impact factor: 4.164

2.  Regulation of uridine diphosphate glucuronosyltransferase during the acute-phase response.

Authors:  S I Strasser; M L Mashford; P V Desmond
Journal:  J Gastroenterol Hepatol       Date:  1998-01       Impact factor: 4.029

3.  Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line.

Authors:  E Lévesque; M Beaulieu; C Guillemette; D W Hum; A Bélanger
Journal:  Endocrinology       Date:  1998-05       Impact factor: 4.736

4.  Effects of B-Blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure.

Authors:  Reinaldo B Bestetti; Ana Paula Otaviano; Augusto Cardinalli-Neto; Bianca Faria da Rocha; Tatiana A D Theodoropoulos; José A Cordeiro
Journal:  Int J Cardiol       Date:  2010-07-01       Impact factor: 4.164

5.  Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes.

Authors:  M Monshouwer; R F Witkamp; S M Nujmeijer; J G Van Amsterdam; A S Van Miert
Journal:  Toxicol Appl Pharmacol       Date:  1996-04       Impact factor: 4.219

6.  Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.

Authors:  G Cheymol; R Woestenborghs; E Snoeck; R Ianucci; J P Le Moing; L Naditch; J C Levron; J M Poirier
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

7.  A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6.

Authors:  K K Machavaram; L M Almond; A Rostami-Hodjegan; I Gardner; M Jamei; S Tay; S Wong; A Joshi; J R Kenny
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

8.  Expression of UDP-glucuronosyltransferase 1A6 isoform in Caco-2 cells stimulated with lipopolysaccharide.

Authors:  Maria Antonietta Panaro; Pasqua Cavallo; Angela Acquafredda; Antonia Cianciulli; Rosa Calvello; Vincenzo Mitolo
Journal:  Innate Immun       Date:  2009-08-26       Impact factor: 2.680

Review 9.  Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.

Authors:  Arturo J Martí-Carvajal; Joey S W Kwong
Journal:  Cochrane Database Syst Rev       Date:  2016-07-08

10.  Intermediate Monocytes and Cytokine Production Associated With Severe Forms of Chagas Disease.

Authors:  Sergio Gómez-Olarte; Natalia I Bolaños; Mariana Echeverry; Ayda N Rodríguez; Adriana Cuéllar; Concepción J Puerta; Alejandro Mariño; John M González
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.